Clinical trial results indicate depemokimab, an IL‑5 monoclonal antibody, is safe when administered twice yearly in patients with moderate‑to‑severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, according to newly released data. The dosing schedule aims to reduce administration burden while maintaining biologic activity against IL‑5‑driven eosinophilia. Safety data from the studies showed an acceptable tolerability profile, and investigators reported sustained biomarker suppression consistent with IL‑5 pathway inhibition. Sponsors now plan to advance regulatory discussions on labeling and dosing intervals to position depemokimab as a low‑frequency biologic option. If confirmed in larger, longer studies, twice‑annual administration could disrupt current market dynamics that favor more frequent dosing regimens and improve adherence. Payers will scrutinize comparative efficacy, cost per dose, and real‑world adherence benefits when evaluating formulary placement. Developers and investors will monitor upcoming efficacy readouts and head‑to‑head comparisons to establish depemokimab’s commercial and clinical differentiation.